drug
(azilsartan medoxomil + chlorthalidone)
Marketedupdated 5mo agoby Azurity Pharmaceuticals Inc
Approvedcommunity read0 votes
indications
investigational
Hypertension
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 26, 2028
~1.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Jul 1, 2031method-of-use (U-3)US 93872494.7y
- Jul 1, 2031method-of-use (U-3)US 93872494.7y
- Feb 4, 2030formulationUS 91692383.3y
- Feb 4, 2030formulationUS 91692383.3y
- Mar 26, 2028formulationUS 90669361.5y
- Mar 26, 2028formulationUS 90669361.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that